Background
Methods
Study design and study population
6MWT
HRQL assessments
Assessment of clinical parameters
Statistical analysis
Results
Patient characteristics and SF-36 and SGRQ scores
Variable | |
---|---|
Age, years | 68 (64–75) |
Sex, Male/Female | 23 (22)/80 (78) |
Disease duration, years | 5.8 (2.3–10.1) |
BMI, kg/m2 | 19.2 (17.5–20.4) |
Smoking status | |
Never/ Former/ Current | 92 (89)/11 (11)/0 (0) |
Charlson comorbidity index | 4 (4–5) |
Underlying pulmonary diseases | |
Old pulmonary tuberculosis | 11 (11) |
Bronchial asthma | 4 (4) |
Lung cancer | 1 (1) |
Sputum findings for NTM infection within the previous year | |
Smear/culture positivity | 31 (30)/62 (60) |
%FVC, % | 94 (80–107) |
%FEV1, % | 87 (73–98) |
FEV1/FVC < 70% | 35 (34) |
%FEV1 < 80% | 39 (38) |
Presence of cavitary lesions | 31 (30.1) |
Radiological pattern | |
NB/FC/NB + FC/unclassified | 81 (78.6)/3 (2.9)/15 (14.5)/4 (3.9) |
SF-36 scores | |
PCS | 48 (38–54) |
MCS | 51 (42–56) |
RCS | 48 (43–54) |
SGRQ scores | |
Symptoms | 31 (15–48) |
Activity | 24 (6–48) |
Impacts | 9 (3–29) |
Total | 19 (9–36) |
6MWT parameters
Variables | |
---|---|
6MWD, m | 410 (365–450) |
Initial SpO2, % | 96 (96–97) |
Lowest SpO2, % | 94 (92–95) |
Initial heart rate, beats/minute | 76 (67–85) |
Final heart rate, beats/minute | 106 (97–116) |
Final Borg scale score | 0.5 (0.5–2) |
DSP, m% | 385 (338–423) |
DA, units | 32 (27–40) |
Correlations among 6MWT parameters and clinical parameters
Age | Disease duration | BMI | CCI | %FVC | %FEV1 | 6MWD | Initial SpO2 | Lowest SpO2 | Initial HR | Final HR | FBS | DSP | DA | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | ||||||||||||||
Disease duration | − 0.09 | |||||||||||||
BMI | 0.01 | 0.10 | ||||||||||||
CCI | 0.32‡ | − 0.04 | 0.09 | |||||||||||
%FVC | − 0.06 | − 0.08 | 0.21* | − 0.05 | ||||||||||
%FEV1 | 0.05 | −0.19 | 0.02 | − 0.01 | 0.78§ | |||||||||
6MWD | −0.34‡ | −0.03 | − 0.16 | − 0.16 | 0.18 | 0.21* | ||||||||
Initial SpO2 | −0.03 | −0.18 | −0.12 | −0.05 | 0.21* | 0.32‡ | 0.08 | |||||||
Lowest SpO2 | −0.07 | −0.11 | − 0.05 | − 0.08 | 0.23* | 0.27† | 0.03 | 0.44§ | ||||||
Initial HR | −0.06 | 0.06 | − 0.24* | − 0.11 | −0.13 | −0.05 | −0.01 | −0.17 | −0.17 | |||||
Final HR | −0.16 | −0.04 | −0.07 | −0.13 | −0.18 | −0.11 | 0.18 | −0.17 | −0.17 | 0.56§ | ||||
FBS | 0.28† | 0.23* | − 0.09 | 0.28† | −0.22* | − 0.12 | −0.17 | −0.05 | −0.08 | −0.002 | −0.04 | |||
DSP | −0.35‡ | −0.05 | −0.15 | −0.17 | 0.23* | 0.26† | 0.99§ | 0.14 | 0.16 | −0.03 | 0.16 | −0.17 | ||
DA | 0.06 | 0.17 | 0.07 | 0.08 | −0.25* | − 0.29† | −0.01 | −0.54§ | −0.95§ | 0.20* | 0.24* | 0.11 | −0.14 |
Correlations among 6MWT parameters or clinical parameters and SF-36 and SGRQ scores
SGRQ | SF-36 | |||||||
---|---|---|---|---|---|---|---|---|
Symptoms | Activity | Impacts | Total | PCS | MCS | RCS | ||
SGRQ | Symptoms | |||||||
Activity | 0.51§ | |||||||
Impacts | 0.68§ | 0.67§ | ||||||
Total | 0.77§ | 0.88§ | 0.91§ | |||||
SF-36 | PCS | −0.44§ | −0.73§ | −0.60§ | −0.70§ | |||
MCS | −0.32‡ | −0.27† | −0.28† | −0.29† | 0.08 | |||
RCS | −0.28† | −0.42§ | −0.40§ | −0.44§ | 0.25* | 0.15 | ||
6WMT | 6MWD | −0.27† | −0.54§ | −0.32† | −0.44§ | 0.39§ | 0.08 | 0.20* |
Initial SpO2 | 0.0002 | −0.12 | −0.08 | −0.09 | 0.05 | −0.15 | −0.09 | |
Lowest SpO2 | −0.15 | −0.14 | −0.21 | −0.19 | 0.10 | −0.01 | −0.05 | |
Initial HR | 0.16 | 0.03 | 0.15 | 0.11 | −0.09 | 0.03 | −0.06 | |
Final HR | 0.11 | −0.04 | 0.04 | 0.03 | 0.07 | 0.00 | −0.02 | |
FBS | 0.34‡ | 0.56§ | 0.54§ | 0.58§ | −0.50§ | −0.17 | −0.24* | |
DSP | −0.29† | −0.55§ | −0.33‡ | −0.46§ | 0.40§ | 0.06 | 0.19 | |
DA | 0.14 | 0.12 | 0.19 | 0.17 | −0.09 | 0.04 | 0.07 | |
Clinical parameters | Age | 0.09 | 0.45§ | 0.22* | 0.36‡ | −0.51§ | 0.10 | −0.18 |
Disease duration | 0.16 | 0.13 | 0.11 | 0.18 | −0.06 | − 0.02 | −0.01 | |
BMI | −0.30† | −0.08 | − 0.27† | −0.22* | 0.14 | 0.07 | 0.20* | |
CCI | −0.09 | 0.33‡ | 0.13 | 0.19 | −0.35‡ | 0.04 | −0.05 | |
%FVC | −0.41§ | −0.28† | − 0.43§ | −0.43§ | 0.15 | −0.03 | 0.07 | |
%FEV1 | −0.34‡ | −0.26† | − 0.32‡ | −0.35‡ | 0.07 | −0.03 | − 0.003 |
Comparisons of 6MWT parameters and questionnaire scores between patients with cavitary lesions and those without
Multivariate analysis for predictors of SGRQ and SF-36 scores
HRQL | Determinants | P-value | Cumulative R2, % |
---|---|---|---|
SGRQ scores | |||
Symptoms | %FVC | 0.0002 | 14.6 |
Sex | 0.0076 | 21.2 | |
BMI | 0.0303 | 27.9 | |
Activity | DSP | < 0.0001 | 33.5 |
FBS | < 0.0001 | 51.3 | |
BMI | 0.0248 | 54.0 | |
Impacts | FBS | < 0.0001 | 20.6 |
%FVC | 0.0020 | 28.7 | |
6MWD | 0.0192 | 33.0 | |
BMI | 0.0048 | 38.9 | |
Total | FBS | < 0.0001 | 24.3 |
6MWD | < 0.0001 | 39.2 | |
BMI | 0.0005 | 47.0 | |
%FVC | 0.0483 | 49.4 | |
SF-36 | |||
PCS | FBS | < 0.0001 | 22.4 |
6MWD | < 0.0001 | 36.2 | |
Age | 0.0014 | 43.2 | |
Sex | 0.0179 | 46.8 | |
Disease duration | 0.0462 | 49.2 |